Revolution Medicines, Inc. (RVMD) is a pharmaceutical company specializing in the research and development of new drugs designed to address major unmet needs in the treatment of cancer. The company has a market capitalization of over $1 billion and is based in Redwood City, California.
Founded in 2014, Revolution Medicines focuses on harnessing the inherent power of the body's immune system to treat cancer, with a specific emphasis on targeting the biological intricacies of cancer cells. They are simultaneously advancing their research by using innovative scientific and clinical strategies to develop effective, patient-friendly medications. The company has strategically propelled its research on never before targeted molecules in cancer pathways that may offer game-changing treatment strategies for patients suffering from a variety of cancers.
One of the company's most notable programs focuses on a pioneering approach to target mutations in the RAS gene, which is one of the most common genetic drivers of cancer. They are earnestly working to create potential first-in-class drugs that can silence this gene, thus preventing it from influencing the growth and spread of cancer cells.
Revolution Medicines, Inc. operates under the leadership of an esteemed and experienced team of biotech and pharmaceutical professionals. The company's Chief Executive Officer, Dr. Mark Goldsmith, has an impressive career background in biotechnology and clinical research. He has overseen the growth of Revolution Medicines from a research-driven startup to a leading player in the world of oncology therapeutics.
The company continuously demonstrates its commitment to groundbreaking research. To aid their development efforts, Revolution Medicines has entered into strategic collaborations with leading pharmaceutical and biomedical companies. Collaborations with companies such as Sanofi and Frontier Medicines have strengthened their R&D capabilities while enhancing their focus on transforming drug discovery for the benefit of cancer patients.
As it stands, the company has a promising pipeline of innovative cancer therapeutics. The anti-cancer drugs which are in the clinical and preclinical development stages are hoped to set new benchmarks in the oncology therapeutics sector. With their advanced focus on precision oncology, Revolution Medicines, Inc. is undoubtedly making great strides in the battle against cancer.
In conclusion, Revolution Medicines, Inc. exemplifies how a commitment to robust scientific investigation combined with strategic collaborations can propel a company to the forefront of health innovation. With its unique approach to drug discovery and formidable dedication to patients, Revolution Medicines stands out as a key player in the endeavor to conquer cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Kevan Shokat, a professor at UCSF and co-founder of Revolution Medicines Inc., has won a $1 million prize for his work on Rasonque, a pancreatic cancer drug. Shokat is a Howard Hughes investigator and a key scientific figure behind several biotech companies. This award recognizes his persistence and contributions to groundbreaking cancer research.
Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its metastatic pancreatic cancer drug RASONQUE, causing its stock to rise significantly. For investors seeking exposure to such pharmaceutical successes while diversifying risk, Royalty Pharma (RPRX) offers an alternative by investing in drug royalties across multiple companies, including RASONQUE. Royalty Pharma provides a safer investment path with a diversified portfolio and dividend income, contrasting with the higher-risk, higher-reward profile of holding a single stock like Revolution Medicines.
Revolution Medicines (RVMD) saw a 4.8% increase in its stock price, largely attributed to a new "Buy" rating from Goldman Sachs, which highlighted confidence in the company's oncology platform. This momentum is further bolstered by the FDA's recent Breakthrough Therapy Designation for RASONQUE in metastatic pancreatic cancer, signaling the company's transition into a commercial-stage oncology firm. The article also details recent insider trading activity, institutional holdings, and analyst price targets for RVMD.
Revolution Medicines has secured a lease for 672,000 square feet at the Pacific Shores Center in Redwood City, formerly a Google campus. This deal marks Silicon Valley's second-largest office lease this year and signifies a trend of investors repurposing older tech campuses for new tenants. The move highlights a shift in the Silicon Valley office market.
Revolution Medicines (RVMD) shares have risen 6.6% since its last earnings report, outperforming the S&P 500. However, the company reported a wider-than-expected Q2 2026 loss with no revenues, and its operating expense outlook for 2026 has increased significantly. Analyst estimates have shown a downward trend, leading to a Zacks Rank #3 (Hold) for the stock.
Revolution Medicines (NASDAQ: RVMD) recently received FDA approval for RASONQUE, a broad RAS-targeted therapy for metastatic pancreatic cancer, a significant medical breakthrough that nearly doubled median overall survival in trials. Despite the breakthrough, the stock's price remained relatively flat on the news, as the approval was largely "priced in" after a 41% surge when trial data was initially presented months prior. The company now faces the challenge of commercial execution, with rising operating expenses and a widened net loss, making successful market penetration and label expansion critical for its future stock performance.